This article is a correction to:
Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite
Chandrashekhar Honrao1
Xiaoyu Ma1
Shashank Kulkarni1Vinit Joshi1
Michael Malamas1Alexander Zvonok2JodiAnne Wood1Roger A. Kautz3,4†David Strand5Jason J. Guo1,3,4*Alexandros Makriyannis1,2,4*- 1Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States
- 2MAK Scientific LLC, Burlington, MA, United States
- 3Barnett Institute for Chemical and Biological Analysis, Northeastern University, Boston, MA, United States
- 4Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, United States
- 5Protasis Corporation, Seabrook, NH, United States
A corrigendum on
Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite
by Honrao, C., Ma, X., Kulkarni, S., Joshi, V., Malamas, M., Zvonok, A., Wood, J., Strand, D., Guo, J. J. and Makriyannis, A., Front. Pharmacol. 11:575691. doi:10.3389/fphar.2020.575691
Roger A. Kautz was not included as an author in the published article. The corrected Author Contributions Statement appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Author Contributions
CH: Designed and conducted experiments. XM and VJ: Metabolite scale up and NMR experiments. JW: Conducted animal PK experiments and data analysis. SK, AZ, and MM: Synthesized compound for studies and metabolite M1 for confirmation. RK and DS: assisted in setting up the microcoil probe and troubleshooting. CH, XM, and JG: Analyzed data and wrote the manuscript. JG and AM: Principal investigators oversaw the project, provided lab resources, and edited the manuscript.
Keywords: metabolite identification, LC-MS, micro-coil NMR, Adamantyl metabolism, di-hydroxyl adamantyl metabolite, CYP3A4 metabolism, CB2 agonist, cannabinoid metabolism
Citation: Honrao C, Ma X, Kulkarni S, Joshi V, Malamas M, Zvonok A, Wood J, Kautz RA, Strand D, Guo JJ and Makriyannis A (2021) Corrigendum: Metabolic Profiling of a CB2 Agonist, AM9338, Using LC-MS and Microcoil-NMR: Identification of a Novel Dihydroxy Adamantyl Metabolite. Front. Pharmacol. 12:630274. doi: 10.3389/fphar.2021.630274
Received: 17 November 2020; Accepted: 18 February 2021;
Published: 22 April 2021.
Approved by:
Frontiers in Pharmacology Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Honrao, Ma, Kulkarni, Joshi, Malamas, Zvonok, Wood, Kautz, Strand, Guo and Makriyannis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jason J Guo, j.guo@northeastern.edu; Alexandros Makriyannis, a.makriyannis@northeastern.edu
†Deceased.